DDInter1700 DDInter1676
Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Somatrem {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fostemsavir
Somatrem {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Somatrem {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluvastatin
Somatrem {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Larotrectinib
Somatrem {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Somatrem may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Somatrem may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Somatrem may lead to a major life threatening interaction when taken with Bexarotene